Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 998 participants.

Also called NCT02476006

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 998 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02476006
  • EudraCT 2015-000620-28
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Poland, Romania, Slovakia, Slovenia, Spain, Switzerland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02476006. Allocation not applicable; no masking; primary purpose treatment. Start 2015-06-23 (actual); primary completion 2019-04-12 (actual). Results posted on 2020-03-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)
Condition
Hypercholesterolemia
Intervention (Drug)
ALIROCUMAB SAR236553 (REGN727)
Intervention (Drug)
placebo (for injection training only)
Intervention (Drug)
ezetimibe
Intervention (Drug)
atorvastatin
Intervention (Drug)
rosuvastatin
Intervention (Drug)
simvastatin
Lead sponsor
Sanofi (class: industry)
Collaborator
Regeneron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct02476006
Content hash
8d2320ee061b89a1434ac5b410748c9482d99e4536c7789fe55697dd4b2e54e9